Novo Nordisk's Q3 Cash Flow Raise Reinforces Bull Case, Though Stock Lags
Read source articleWhat happened
Novo Nordisk's Q3 2026 results showed improved cost discipline, with gross margin rising to 82.1% and free cash flow of DKK 28.4 billion, prompting management to raise full-year FCF guidance to DKK 60–70 billion. The Seeking Alpha article reiterates a Strong Buy, arguing the stock is inexpensive at 10.89 times non-GAAP earnings despite these improvements. Oral Wegovy is scaling internationally, and lower-dose CagriSema data plus an expected FDA decision support a potential early 2027 launch. However, the market has not yet rewarded the stock, which trades around $41.6, near the lower end of our base-case value range, reflecting persistent concerns about 2027 pricing pressure and competition. Overall, the news aligns with our existing POTENTIAL BUY rating but does not yet alter the key catalysts or risks we are monitoring.
Implication
The raised free cash flow guidance indicates that Novo's cost discipline is translating into improved cash generation, which supports the valuation argument at current multiples. However, the stock's failure to re-rate despite the positive news suggests the market remains focused on the January 2027 list-price reset and competitive share losses. Investors should monitor whether oral Wegovy can sustain its >50% U.S. branded obesity new-patient share while expanding beyond 20 markets by H1 2027. The CagriSema FDA decision in Q4 2026 is the next critical catalyst; a delay or rejection would undermine the early 2027 launch assumption and likely pressure the stock further. For now, the thesis remains intact but not enhanced; position sizing should reflect the scenario probabilities, with attractive entry near $39 and trim above $50.
Thesis delta
The master report rated NVO a POTENTIAL BUY with conviction 4.0. The new information (FCF raise, gross margin improvement) is consistent with the base case but does not materially shift probabilities. The thesis delta is minimal: no change to rating or conviction, but near-term execution risk appears slightly reduced given better cash flow visibility.
Confidence
Moderate